PCN Insights, News, Videos, and More

Olusola Ajilore, MD, PhD, provides an overview of digital therapeutics for telehealth practitioners.

The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...

In 3 pediatric cohorts in Spain, children with sleep problems at ages 8 and 9 were at increased risk of attention-deficit/hyperactivity disorder (ADHD) symptoms in preadolescence. Researchers published their findings in the European Journal...

Buprenorphine, whether administered sublingually or subcutaneously, appears to be an effective option for the treatment of opioid use disorder (OUD) with fentanyl use.

Nishi Bhopal, MD, clarifies 5 common misconceptions about sleep medicine for mental health care practice.

Adding internet and phone support to a family practitioner review for possible discontinuation of long-term antidepressants provided small additional benefits.

In this video, Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, offers practical guidance for telehealth providers screening for, diagnosing, and treating attention-deficit/hyperactivity disorder (ADHD) in pediatric and/or adult patients.